JOHN B HENNEMAN III Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for JOHN B HENNEMAN III.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of JOHN B HENNEMAN III. JOHN B HENNEMAN III is Director in Anika Therapeutics, Inc. ($ANIK) and Chief Administrative Officer in NEWLINK GENETICS CORP ($NLNK) and EVP, Chief Financial Officer in NEWLINK GENETICS CORP ($NLNK) and Director in Accretive Health, Inc. ($AH) and Director in SeaSpine Holdings Corp ($SPNE) and in Aprea Therapeutics, Inc. ($APRE).
Latest Insider Trading Transactions of JOHN B HENNEMAN III
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ANIK, APRE, NLNK, AH, SPNE
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 04 2021 | SPNE | SeaSpine Holdings ... | HENNEMAN JOHN B III | Director | Grant | A | 0.00 | 6,253 | 0 | 66,711 | 60.5 K to 66.7 K (+10.34 %) |
May 24 2021 | AH | R1 RCM INC. | HENNEMAN JOHN B III | Director | Option Exercise | A | 0.00 | 5,151 | 0 | 5,151 | |
Apr 02 2021 | AH | R1 RCM INC. | HENNEMAN JOHN B III | Director | Option Exercise | A | 24.98 | 1,490 | 37,220 | 1,490 | |
Jan 05 2021 | AH | R1 RCM INC. | HENNEMAN JOHN B III | Director | Option Exercise | A | 23.49 | 1,625 | 38,171 | 1,625 | |
Oct 02 2020 | AH | R1 RCM INC. | HENNEMAN JOHN B III | Director | Option Exercise | A | 17.54 | 2,186 | 38,342 | 2,186 | |
Sep 08 2020 | ANIK | Anika Therapeutics ... | HENNEMAN JOHN B III | Director | Grant | A | 0.00 | 9,310 | 0 | 9,310 | 0 to 9.3 K |
Aug 05 2020 | SPNE | SeaSpine Holdings ... | HENNEMAN JOHN B III | Director | Sell | S | 15.00 | 10,000 | 150,000 | 60,458 | 70.5 K to 60.5 K (-14.19 %) |
Jul 02 2020 | AH | R1 RCM INC. | HENNEMAN JOHN B III | Director | Option Exercise | A | 11.78 | 3,249 | 38,273 | 3,249 | |
Jul 01 2020 | APRE | Aprea Therapeutics ... | HENNEMAN JOHN B III | Option Exercise | A | 38.78 | 5,600 | 217,168 | 5,600 | ||
Jun 05 2020 | SPNE | SeaSpine Holdings ... | HENNEMAN JOHN B III | Director | Grant | A | 0.00 | 8,488 | 0 | 70,458 | 62 K to 70.5 K (+13.70 %) |
Apr 03 2020 | AH | R1 RCM INC. | HENNEMAN JOHN B III | Director | Option Exercise | A | 8.41 | 4,542 | 38,198 | 4,542 | |
Apr 03 2020 | AH | R1 RCM INC. | HENNEMAN JOHN B III | Director | Option Exercise | A | 8.41 | 4,542 | 38,198 | 4,542 | |
Jan 03 2020 | AH | R1 RCM INC. | HENNEMAN JOHN B III | Director | Option Exercise | A | 12.69 | 2,851 | 36,179 | 2,851 | |
Jan 03 2020 | AH | R1 RCM INC. | HENNEMAN JOHN B III | Director | Option Exercise | A | 12.69 | 2,851 | 36,179 | 2,851 | |
Oct 07 2019 | APRE | Aprea Therapeutics ... | HENNEMAN JOHN B III | Option Exercise | A | 15.00 | 18,407 | 276,105 | 18,407 | ||
Oct 07 2019 | APRE | Aprea Therapeutics ... | HENNEMAN JOHN B III | Option Exercise | A | 15.00 | 18,407 | 276,105 | 18,407 | ||
Oct 07 2019 | APRE | Aprea Therapeutics ... | HENNEMAN JOHN B III | Buy | P | 15.00 | 5,000 | 75,000 | 5,000 | 0 to 5 K | |
Oct 07 2019 | APRE | Aprea Therapeutics ... | HENNEMAN JOHN B III | Buy | P | 15.00 | 5,000 | 75,000 | 5,000 | 0 to 5 K | |
Oct 03 2019 | AH | R1 RCM INC. | HENNEMAN JOHN B III | Director | Option Exercise | A | 9.05 | 4,025 | 36,426 | 4,025 | |
Jul 02 2019 | AH | R1 RCM INC. | HENNEMAN JOHN B III | Director | Option Exercise | A | 12.65 | 2,846 | 36,002 | 2,846 | |
Apr 02 2019 | AH | R1 RCM INC. | HENNEMAN JOHN B III | Director | Option Exercise | A | 9.57 | 3,684 | 35,256 | 3,684 | |
Jan 03 2019 | AH | R1 RCM INC. | HENNEMAN JOHN B III | Director | Option Exercise | A | 7.89 | 4,285 | 33,809 | 4,285 | |
Oct 03 2018 | AH | R1 RCM INC. | HENNEMAN JOHN B III | Director | Option Exercise | A | 10.01 | 3,319 | 33,223 | 3,319 | |
Oct 02 2018 | NLNK | NEWLINK GENETICS C ... | HENNEMAN JOHN B III | Chief Administrativ ... | Payment of Exercise | F | 2.28 | 2,484 | 5,664 | 55,052 | 57.5 K to 55.1 K (-4.32 %) |
Aug 29 2018 | SPNE | SeaSpine Holdings ... | HENNEMAN JOHN B III | Director | Sell | S | 14.65 | 3,407 | 49,913 | 54,708 | 58.1 K to 54.7 K (-5.86 %) |
Aug 29 2018 | SPNE | SeaSpine Holdings ... | HENNEMAN JOHN B III | Director | Sell | S | 14.65 | 2,029 | 29,725 | 58,115 | 60.1 K to 58.1 K (-3.37 %) |
Aug 29 2018 | SPNE | SeaSpine Holdings ... | HENNEMAN JOHN B III | Director | Sell | S | 14.72 | 4,564 | 67,182 | 60,144 | 64.7 K to 60.1 K (-7.05 %) |
Jun 13 2018 | SPNE | SeaSpine Holdings ... | HENNEMAN JOHN B III | Director | Option Exercise | M | 12.44 | 17,398 | 216,431 | 0 | |
Jun 13 2018 | SPNE | SeaSpine Holdings ... | HENNEMAN JOHN B III | Director | Buy | M | 12.44 | 17,398 | 216,431 | 64,708 | 47.3 K to 64.7 K (+36.77 %) |
May 31 2018 | SPNE | SeaSpine Holdings ... | HENNEMAN JOHN B III | Director | Grant | A | 0.00 | 4,429 | 0 | 47,310 | 42.9 K to 47.3 K (+10.33 %) |
May 31 2018 | SPNE | SeaSpine Holdings ... | HENNEMAN JOHN B III | Director | Grant | A | 0.00 | 4,429 | 0 | 47,310 | 42.9 K to 47.3 K (+10.33 %) |
May 31 2018 | SPNE | SeaSpine Holdings ... | HENNEMAN JOHN B III | Director | Grant | A | 0.00 | 8,857 | 0 | 42,881 | 34 K to 42.9 K (+26.03 %) |
May 31 2018 | SPNE | SeaSpine Holdings ... | HENNEMAN JOHN B III | Director | Grant | A | 0.00 | 8,857 | 0 | 42,881 | 34 K to 42.9 K (+26.03 %) |
Apr 03 2018 | AH | R1 RCM INC. | HENNEMAN JOHN B III | Director | Option Exercise | A | 7.07 | 4,770 | 33,724 | 4,770 | |
Mar 13 2018 | NLNK | NEWLINK GENETICS C ... | HENNEMAN JOHN B III | EVP, Chief Financia ... | Option Exercise | A | 7.85 | 122,000 | 957,700 | 122,000 | |
Jan 04 2018 | NLNK | NEWLINK GENETICS C ... | HENNEMAN JOHN B III | EVP, Chief Financia ... | Payment of Exercise | F | 10.06 | 1,323 | 13,309 | 57,536 | 58.9 K to 57.5 K (-2.25 %) |
Jan 04 2018 | NLNK | NEWLINK GENETICS C ... | HENNEMAN JOHN B III | EVP, Chief Financia ... | Payment of Exercise | F | 8.47 | 164 | 1,389 | 58,859 | 59 K to 58.9 K (-0.28 %) |
Oct 03 2017 | AH | R1 RCM INC. | HENNEMAN JOHN B III | Director | Option Exercise | A | 3.76 | 9,169 | 34,475 | 9,169 | |
Oct 02 2017 | NLNK | NEWLINK GENETICS C ... | HENNEMAN JOHN B III | EVP, Chief Financia ... | Payment of Exercise | F | 10.18 | 2,789 | 28,392 | 56,544 | 59.3 K to 56.5 K (-4.70 %) |
Jun 15 2017 | SPNE | SeaSpine Holdings ... | HENNEMAN JOHN B III | Director | Grant | A | 0.00 | 15,121 | 0 | 34,024 | 18.9 K to 34 K (+79.99 %) |
Apr 05 2017 | AH | R1 RCM INC. | HENNEMAN JOHN B III | Director | Option Exercise | A | 3.08 | 10,512 | 32,377 | 10,512 | |
Jan 05 2017 | NLNK | NEWLINK GENETICS C ... | HENNEMAN JOHN B III | EVP, Chief Financia ... | Option Exercise | A | 10.55 | 137,500 | 1,450,625 | 137,500 | |
Jan 05 2017 | NLNK | NEWLINK GENETICS C ... | HENNEMAN JOHN B III | EVP, Chief Financia ... | Payment of Exercise | F | 11.04 | 1,323 | 14,606 | 58,612 | 59.9 K to 58.6 K (-2.21 %) |
Jan 05 2017 | NLNK | NEWLINK GENETICS C ... | HENNEMAN JOHN B III | EVP, Chief Financia ... | Payment of Exercise | F | 10.28 | 164 | 1,686 | 59,935 | 60.1 K to 59.9 K (-0.27 %) |
Jan 04 2017 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Option Exercise | A | 2.29 | 14,098 | 32,284 | 14,098 | |
Oct 05 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Option Exercise | A | 2.42 | 13,762 | 33,304 | 13,762 | |
Oct 04 2016 | NLNK | NEWLINK GENETICS C ... | HENNEMAN JOHN B III | EVP, Chief Financia ... | Payment of Exercise | F | 15.02 | 2,789 | 41,891 | 60,099 | 62.9 K to 60.1 K (-4.43 %) |
Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.80 | 12,500 | 22,500 | 50,000 | 37.5 K to 50 K (+33.33 %) |
Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.80 | 1,500 | 2,700 | 37,500 | 36 K to 37.5 K (+4.17 %) |
Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.81 | 14,500 | 26,245 | 36,000 | 21.5 K to 36 K (+67.44 %) |
Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.81 | 1,500 | 2,715 | 21,500 | 20 K to 21.5 K (+7.50 %) |
Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.80 | 10,000 | 17,975 | 20,000 | 10 K to 20 K (+100.00 %) |
Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.80 | 7,800 | 14,040 | 10,000 | 2.2 K to 10 K (+354.55 %) |
Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.79 | 500 | 895 | 2,200 | 1.7 K to 2.2 K (+29.41 %) |
Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.77 | 500 | 885 | 1,700 | 1.2 K to 1.7 K (+41.67 %) |
Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.79 | 500 | 893 | 1,200 | 700 to 1.2 K (+71.43 %) |
Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.77 | 100 | 177 | 700 | 600 to 700 (+16.67 %) |
Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.79 | 500 | 895 | 600 | 100 to 600 (+500.00 %) |
Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.78 | 100 | 178 | 100 | 0 to 100 |
Aug 11 2016 | NLNK | NEWLINK GENETICS C ... | HENNEMAN JOHN B III | EVP, Chief Financia ... | Option Exercise | A | 10.78 | 150,000 | 1,617,000 | 150,000 | |
Jul 06 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Option Exercise | A | 2.00 | 15,385 | 30,770 | 15,385 | |
Jun 09 2016 | SPNE | SeaSpine Holdings ... | HENNEMAN JOHN B III | Director | Option Exercise | A | 9.99 | 13,920 | 139,061 | 13,920 | |
Jun 09 2016 | SPNE | SeaSpine Holdings ... | HENNEMAN JOHN B III | Director | Grant | A | 0.00 | 10,010 | 0 | 18,903 | 8.9 K to 18.9 K (+112.56 %) |
Apr 05 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Option Exercise | A | 2.53 | 12,048 | 30,481 | 12,048 | |
Feb 24 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Option Exercise | A | 2.61 | 405,111 | 1,057,340 | 405,111 | |
Jan 06 2016 | NLNK | NEWLINK GENETICS C ... | HENNEMAN JOHN B III | EVP, Chief Financia ... | Option Exercise | A | 34.73 | 46,351 | 1,609,770 | 46,351 | |
Jan 06 2016 | NLNK | NEWLINK GENETICS C ... | HENNEMAN JOHN B III | EVP, Chief Financia ... | Sell | S | 35.74 | 175 | 6,255 | 62,316 | 62.5 K to 62.3 K (-0.28 %) |
Jan 06 2016 | NLNK | NEWLINK GENETICS C ... | HENNEMAN JOHN B III | EVP, Chief Financia ... | Grant | A | 0.00 | 16,201 | 0 | 62,491 | 46.3 K to 62.5 K (+35.00 %) |
Jan 05 2016 | SPNE | SeaSpine Holdings ... | HENNEMAN JOHN B III | Director | Option Exercise | A | 17.18 | 3,858 | 66,280 | 3,858 | |
Oct 05 2015 | NLNK | NEWLINK GENETICS C ... | HENNEMAN JOHN B III | EVP, Chief Financia ... | Payment of Exercise | F | 35.32 | 4,199 | 148,309 | 46,290 | 50.5 K to 46.3 K (-8.32 %) |
Aug 04 2015 | SPNE | SeaSpine Holdings ... | HENNEMAN JOHN B III | Director | Option Exercise | A | 15.68 | 58,559 | 918,205 | 58,559 | |
May 14 2015 | NLNK | NEWLINK GENETICS C ... | HENNEMAN JOHN B III | EVP, Chief Financia ... | Buy | P | 37.30 | 3,000 | 111,900 | 50,489 | 47.5 K to 50.5 K (+6.32 %) |
May 14 2015 | NLNK | NEWLINK GENETICS C ... | HENNEMAN JOHN B III | EVP, Chief Financia ... | Gift | G | 0.00 | 300 | 0 | 47,489 | 47.8 K to 47.5 K (-0.63 %) |
Page: 1